

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – TA Guidance in development

#### STA vemurafenib for the treatment of unresectable locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

#### Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

No issues relating to equality were raised during the scoping process.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

N/A

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

N/A

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other

groups? If so, what are the barriers to access for the specific group?
N/A

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?
N/A

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
N/A

**Approved by Associate Director (name):** Janet Robertson

**Date:** October 2012

### **Final appraisal determination**

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?
No equality issues were identified during the consultation process.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?
N/A

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

N/A

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

N/A

**Approved by Centre or Programme Director (name):** Meindert Boysen

**Date:** 10/12/12